Investor Presentation
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shree Ganesh Remedies Ltd, a specialty chemical manufacturer, reported flat revenue of ₹109.29 crore in FY26 (vs ₹108.60 crore in FY25) with PAT falling 23% to ₹17.77 crore. EBITDA declined 11% to ₹35.02 crore with margins compressing to 32.0% from 36.1% a year ago. Management explicitly described FY26 as a "year of consolidation" as guided throughout the year, using the period to deepen foundations: securing approvals, advancing newer molecule development, and building capabilities. Key catalysts ahead include Block 7 commissioning targeted for Q2FY27, a newly operational pilot plant, and CRAMS projects (spanning agrochemicals, pharma, and electronics applications in Europe and Japan) successfully completing pilot trials and moving toward commercial production. Long-term borrowings reduced from ₹29.48 crore to ₹21.25 crore. The company cited persistent headwinds including Europe slowdown, geopolitical uncertainty, raw material volatility, and customer purchase deferrals.
The flat revenue and 23% PAT decline signal near-term earnings pressure, but management's framing of FY26 as guided consolidation and the slate of upcoming operational milestones (Block 7 commissioning, commercial CRAMS ramp-up) suggest the market may already be pricing in weak near-term performance with upside tied to execution of the growth platform.